Immunologic Research

, Volume 37, Issue 3, pp 161–175 | Cite as


Their role in bacterial infection and inflammation
  • Pieter-Jan Haas
  • Jos van Strijp


Activation of the complement system plays a crucial role in the pathogenesis of infection and inflammation. Especially the complement activation products C3a and C5a, known as the anaphylatoxins, are potent proinflammatory mediators. In addition to their evident role in innate immunity, it is clear that the anaphylatoxins also play a role in regulation of adaptive immune responses. The anaphylatoxins play a role in a variety of infectious and inflammatory diseases like sepsis, ischemia-reperfusion injury, immune complex diseases, and hypersensitivity diseases like asthma. In this review we discuss the role of anaphylatoxins in infection and inflammation. Furthermore, we focus on bacterial complement evasion strategies that can provide tools for further research on pathogenesis of infectious diseases and a better understanding of the role of complement and anaphylatoxins in infection and inflammation.

Key Words

Anaphylatoxins C3a C4a C5a Infection Inflammation Complement Immune evasion 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    HuberLang M, Sarma JV, Zetoune FS, et al: Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006;12:682–687.Google Scholar
  2. 2.
    Barnum SR, Ames RS, Maycox PR, et al: Expression of the complement C3a and C5a receptors after permanent focal ischemia: an alternative interpretation. Glia 2002;38:169–173.PubMedGoogle Scholar
  3. 3.
    Dahinden CA, Bischoff SC, Brunner T, Krieger M, Takafuji, S, de Weck, AL: Regulation of mediator release by human basophils: importance of the sequence and time of addition in the combined action of different agonists. Int Arch Allergy Appl Immunol 1991;94:161–164.PubMedGoogle Scholar
  4. 4.
    Elsner J, Oppermann M, Czech W, Dobos G, Schöpf E, Norgauer J, Kapp, A: C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 1994;24:518–522.PubMedGoogle Scholar
  5. 5.
    Epps DEV, Simpson, SJ, Johnson, R: Relationships of C5a receptor modulation to the functional responsiveness of human polymorphonuclear leukocytes to C5a. J Immunol 1993;150:246–252.PubMedGoogle Scholar
  6. 6.
    Hartmann K, Henz BM, Krüger-Krasagakes S, et al: C3a and C5a stimulate chemotaxis of human mast cells. Blood 1997;89:2863–2870.PubMedGoogle Scholar
  7. 7.
    Nilsson G, Johnell M, Hammer CH, et al: C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol 1996;157:1693–1698.PubMedGoogle Scholar
  8. 8.
    Norgauer J, Dobos G, Kownatzki E, et al: Complement fragment C3a stimulates Ca2+ influx in neutrophils via a pertussis-toxin-sensitive G-protein. Eur J Biochem 1993;217:289–294.PubMedGoogle Scholar
  9. 9.
    Settmacher B, Bock D, Saad H, et al: Modulation of C3a activity: internalization of the human c3a receptor and its inhibition by C5a. J Immunol 1999;162: 7409–7416.PubMedGoogle Scholar
  10. 10. Scholar
  11. 11.
    Beutler B. Innate immunity: an overview. Mol Immunol 2004;40:845–859.PubMedGoogle Scholar
  12. 12.
    Rooijakkers SHM, van Wamel WJB, Ruyken M, van Kessel, KPM, van Strijp, JAG: Anti-opsonic properties of staphylokinase. Microbes Infect 2005;7:476–484.PubMedGoogle Scholar
  13. 13.
    Bokisch VA, Müller-Eberhard HJ, Cochrane CG: Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med 1969;129:1109–1130.PubMedGoogle Scholar
  14. 14.
    Bokisch VA, Dierich MP, Müller-Eberhard HJ: Third component of complement (C3): structural properties in relation to functions. Proc Natl Acad Sci USA 1975;72:1989–1993.PubMedGoogle Scholar
  15. 15.
    Budzko DB, Bokisch VA, Müller-Eberhard HJ: A fragment of the third component of human complement with anaphylatoxin activity. Biochemistry 1971;10: 1166–1172.PubMedGoogle Scholar
  16. 16.
    Gerard NP, Gerard C: Complement in allergy and asthma. Curr Opin Immunol 2002;14:705–708.PubMedGoogle Scholar
  17. 17.
    Hawlisch H, Wills-Karp M, Karp CL, Köhl, J: The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 2004; 41:123–131.PubMedGoogle Scholar
  18. 18.
    Ames RS, Li Y, Sarau HM, et al: Molecular cloning and characterization of the human anaphylatoxin C3a receptor J Biol Chem 1996;271:20231–20234.PubMedGoogle Scholar
  19. 19.
    Fischer WH, Hugli TE: Regulation of B cell functions by C3a and C3a(desarg): suppression of TNF-alpha, IL-6, and the polyclonal immune response. J Immunol 1997;159:4279–4286.PubMedGoogle Scholar
  20. 20.
    Francis K, Lewis BM, Akatsu H, et al: Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation. FASEB J 2003;17:2266–2268.PubMedGoogle Scholar
  21. 21.
    Gasque P, Singhrao SK, Neal JW, et al: The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol 1998;160:3543–3554.PubMedGoogle Scholar
  22. 22.
    Monsinjon T, Gasque P, Ischenko A, Fontaine M: C3a binds to the seven transmembrane anaphylatoxin receptor expressed by epithelial cells and triggers the production of IL-8. Febs Lett 2001;487:339–346.PubMedGoogle Scholar
  23. 23.
    Drouin SM, Corry DB, Kildsgaard J, Wetsel RA: Cuting edge: the absence of C3 demonstrates a role for complement in Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2001;167: 4141–4145.PubMedGoogle Scholar
  24. 24.
    Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA: Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2002;169:5926–5933.PubMedGoogle Scholar
  25. 25.
    Humbles AA, Lu B, Nilsson CA, et al: A role for the C3a anaphylatoxin receptor in the effector phase of asthma. Nature 2000;406:998–1001.PubMedGoogle Scholar
  26. 26.
    Cianflone K, Maslowska M, Sniderman AD: Acylation stimulating protein (ASP), an adipocyte autocrine: new directions. Semin Cell Dev Biol 1999;10:31–41.PubMedGoogle Scholar
  27. 27.
    Cianflone K, Xia Z, Chen LY: Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 2003;1609:127–43.PubMedGoogle Scholar
  28. 28.
    Murray I, Köhl J, Cianflone K: Acylation-stimulating protein (ASP): structure-function determinants of cell surface binding and triacylglycerol synthetic activity. Biochem J 1999;342 (Pt 1):41–48.PubMedGoogle Scholar
  29. 29.
    'Xia Z, Stanhope KL, Digitale E, et al: Acylation-stimulating protein (asp)/complement C3a-des-arg deficiency results in increased energy expenditure in mice. J Biol Chem 2004;279:4051–4057.Google Scholar
  30. 30.
    Kalant D, MacLaren R, Cui W, et al: C5L2 is a functional receptor for acylation-stimulating protein. J Biol Chem 2005;280:23936–23944.PubMedGoogle Scholar
  31. 31.
    Gorski JP, Hugli TE, Müller-Eberhard, HJ: C4a: the third anaphylatoxin of the human complement system. Proc Natl Acad Sci USA 1979;76:5299–5302.PubMedGoogle Scholar
  32. 32.
    Meuer S, Hugli TE, Andreatta RH, Hadding U, Bitter-Suermann D. Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). investigations on their ability to induce platelet secretion. Inflammation 1981;5:263–273.PubMedGoogle Scholar
  33. 33.
    Murakami Y, Yamamoto T, Imamichi T, Nagasawa S: Cellular responses of guinea-pig macrophages to C4a; inhibition of C3a-induced O2 generation by C4a. Immunol Lett 1993;36:301–304.PubMedGoogle Scholar
  34. 34.
    Lienenklaus S, Ames RS, Tornetta MA, et al: Human anaphylatox in C4a is a potent agonist of the guinea pig but not the human C3a receptor. J Immunol 1998; 161:2089–2093.PubMedGoogle Scholar
  35. 35.
    Köhl J: Anaphylatoxins and infectious and non-infectious inflammatory diseases. Mol Immunol 2001;38:175–187.PubMedGoogle Scholar
  36. 36.
    Guo RF, Ward, PA: Role of C5a in inflammatory responses. Annu Rev Immunol 2005;23:821–852.PubMedGoogle Scholar
  37. 37.
    Goldstein IM, Weissmann G: Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J Immunol 1974;113:1583–1588.PubMedGoogle Scholar
  38. 38.
    Marder SR, Chenoweth DE, Goldstein IM, Perez, HD: Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a, and C5a-des-arg. J Immunol 1985;134:3325–3331.PubMedGoogle Scholar
  39. 39.
    Sacks T, Moldow CF, Craddock PR, Bowers TK, Jacob HS: Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes an in vitro model of immune vascular damage. J Clin Invest 1978;61:1161–1167.PubMedCrossRefGoogle Scholar
  40. 40.
    Guo RF, Huber-Lang M, Wang X, et al: Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest 2000;106:1271–1280.PubMedGoogle Scholar
  41. 41.
    Guo R, Riedemann NC, Laudes IJ, et al: Altered neutrophil trafficking during sepsis. J Immunol 2002; 169:307–314.PubMedGoogle Scholar
  42. 42.
    Laudes IJ, Chu JC, Sikranth S, et al: Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am J Pathol 2002;160:1867–1875.PubMedGoogle Scholar
  43. 43.
    Laudes IJ, Chu JC, Huber-Lang M, et al: Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol 2002;169:5962–5970.PubMedGoogle Scholar
  44. 44.
    Perianayagam MC, Balakrishnan VS, King AJ, Pereira BJ, G, Jaber, BL. C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway. Kidney Int 2002;61:456–463.PubMedGoogle Scholar
  45. 45.
    Perianayagam MC, Balakrishnan VS, Pereira BJG, Jaber BL. C5a delays apoptosis of human neutrophils via an extracellular signal-regulated kinase and badmediated signalling pathway. Eur J Clin Invest 2004; 34:50–56.PubMedGoogle Scholar
  46. 46.
    Riedemann NC, Guo R, Laudes IJ, et al: C5a receptor and thymocyte apoptosis in sepsis. FASEB J 2002;16:887–888.PubMedGoogle Scholar
  47. 47.
    Rennen HJ, Oyen WJ, Cain SA, Monk PN, Corstens FH, Boerman OC: Tc-99m-labeled C5a and C5a-desarg74 for infection imaging. Nucl Med Biol 2003:30:267–272.PubMedGoogle Scholar
  48. 48.
    Gerard NP, Gerard C: The chemotactic receptor for human C5a anaphylatoxin. Nature 1991;349:614–617.PubMedGoogle Scholar
  49. 49.
    Gerard C, Gerard NP: C5a anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol 1994;12:775–808.PubMedGoogle Scholar
  50. 50.
    Bockaert J, Pin JP: Molecular tinkering of G proteincoupled receptors: an evolutionary success. EMBO J 1999;18:1723–1729.PubMedGoogle Scholar
  51. 51.
    Gao J, Choe H, Bota D, Wright PL, Gerard C, Gerard NP: Sulfation of tyrosine 174 in the human C3a receptor is essential for binding of C3a anaphylatoxin. J Biol Chem 2003;278:37902–37908.PubMedGoogle Scholar
  52. 52.
    Farzan M, Schnitzler CE, Vasilieva N, et al: Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a an aphylatoxin receptor. J Exp Med 2001;193:1059–1066.PubMedGoogle Scholar
  53. 53.
    Chen Z, Zhang X, Gonnella NC, Pellas TC, Boyar WC, Ni F: Residues 21–30 within the extracellular N-terdomain for the C5a anaphylatoxin. J Biol Chem 1998;273:10411–10419.PubMedGoogle Scholar
  54. 54.
    Postma B, Kleibeuker W, Poppelier MJ, et al: Residues 10–18 within the C5a receptor N-terminus compose a binding domain for chemotaxis inhibitory protein ofStaphylococcus aureus. J Biol Chem 2005;280:2020–2027.PubMedGoogle Scholar
  55. 55.
    Rollins TE, Siciliano S, Springer MS: Solubilization of the functional C5a receptor from human polymorphonuclear leukocytes. J Biol Chem 1988;263:520–526.PubMedGoogle Scholar
  56. 56.
    Rollins TE, Siciliano S, Kobayashi S, et al: Purification of the active C5a receptor from human polymorphonuclear leukocytes as a receptor-Gi complex. Proc Natl Acad Sci USA 1991;88:971–975.PubMedGoogle Scholar
  57. 57.
    Siciliano SJ, Rollins TE, DeMartino J, et al: Two-site binding of C5a by its receptor: an alternative binding paradigm for G protein-coupled receptors. Proc Natl Acad Sci USA 1994;91:1214–1218.PubMedGoogle Scholar
  58. 58.
    Wetsel RA: Expression of the complement C5a anaphylatoxin receptor (C5ar) on non-myeloid cells. Immunol Lett 1995;44:183–187.PubMedGoogle Scholar
  59. 59.
    Wetsel RA: Structure, function and cellular expression of complement anaphylatoxin receptors. Curr Opin Immunol 1995;7:48–53.PubMedGoogle Scholar
  60. 60.
    Zwirner J, Fayyazi A, Gotze O: Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 1999;36:877–884.PubMedGoogle Scholar
  61. 61.
    Gerard NP, Hodges MK, Drazen JM, Weller PF, Gerard C: Characterization of a receptor for C5a analphylatoxin on human eosinophils. J Biol Chem 1989;264:1760–1766.PubMedGoogle Scholar
  62. 62.
    Kalant D, Cain SA, Maslowska M, et al: The chemoattractant receptor-like protein C5L2 binds the C3a-desarg77/acylation-stimulating protein. J Biol Chem 2003;278:11123–11129.PubMedGoogle Scholar
  63. 63.
    Cain SA, Monk PN: The orphan receptor c512 has high affinity binding sites for complement fragments C5a and C5a-des-arg(74). J Biol Chem 2002;277:7165–7169.PubMedGoogle Scholar
  64. 64.
    Gerard NP, Lu B, Liu P, et al: An anti-inflammatory function for the complement anaphylatoxin C5-abinding protein, C5L2. J Biol Chem 2005;280:39677–39680.PubMedGoogle Scholar
  65. 65.
    Okinaga S, Slattery D, Humbles A, et al: C5L2, a nonsignaling C5a binding protein. Biochemistry 2003;42:9406–9415.PubMedGoogle Scholar
  66. 66.
    Kawamoto S, Yalcindag A, Laouini D, et al: The anaphylatoxin C3a downregulates the Th2 response to epicutaneously introduced antigen.J Clin Invest 2004;114:399–407.PubMedGoogle Scholar
  67. 67.
    Nakano Y, Morita S, Kawamoto A, Suda T, Chida K, Nakamura H: Elevated complement C3a in plasma from patients with severe acute asthma. J Allergy Clin Immunol 2003;112:525–530.PubMedGoogle Scholar
  68. 68.
    Hasegawa K, Tamari M, Shao C, et al: Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma. Hum Genet 2004;115:295–301.PubMedGoogle Scholar
  69. 69.
    Fischer WH, Jagels MA, Hugli TE: Regulation of Il-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(des-arg). J Immunol 1999;162:453–459.PubMedGoogle Scholar
  70. 70.
    Schwartz LB, Kawahara MS, Hugli TE, Vik D, Fearon DT, Austen KF: Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J Immunol 1983;130:1891–1895.PubMedGoogle Scholar
  71. 71.
    Ali H, Panettieri RAJ: Anaphylatoxin C3a receptors in asthma. Respir Res 2005;6:19.PubMedGoogle Scholar
  72. 72.
    Mastellos D, Andronis C, Persidis A, Lambris JD: Novel biological networks modulated by complement. Clin Immunol 2005;115:225–235.PubMedGoogle Scholar
  73. 73.
    O'Barr SA, Caguioa J, Gruol D, et al: Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 2001;166:4154–4162.PubMedGoogle Scholar
  74. 74.
    Strey CW, Markiewski M, Mastellos D, et al: The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 2003;198:913–923.PubMedGoogle Scholar
  75. 75.
    Guo R, Riedemann NC Ward PA: Role of C5a-C5aR interaction in sepsis. Shock 2004;21:1–7.PubMedGoogle Scholar
  76. 76.
    Nakae H, Endo S, Inada K, Takakuwa T, Kasai T, Yoshida M: Serum complement levels and severity of sepsis. Res Commun Chem Pathol Pharmacol 1994;84:189–195.PubMedGoogle Scholar
  77. 77.
    Huber-Lang M, Sarma VJ, Lu KT, et al: Role of C5a in multiorgan failure during sepsis. J Immunol 2001;166:1193–1199.PubMedGoogle Scholar
  78. 78.
    Höpken U, Mohr M, Strüber A, et al. Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. Eur J Immunol 1996;26:1103–1109.PubMedGoogle Scholar
  79. 79.
    Strieter RM, Kasahara K, Allen RM, et al: Cytokine-induced neutrophil-derived interleukin-8. Am J Pathol 1992;141:397–407.PubMedGoogle Scholar
  80. 80.
    Monsinjon T, Gasque P, Chan P, et al: Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003;17:1003–1014.PubMedGoogle Scholar
  81. 81.
    Pan ZK: Anaphylatoxins C5a and C3a induce nuclear factor kappa B activation in human peripheral blood monocytes. Biochim Biophys Acta 1998;1443:90–98.PubMedGoogle Scholar
  82. 82.
    Huber-Lang MS, Younkin EM, Sarma JV, et al: Complement-induced impairment of innate immunity during sepsis. J Immunol 2002;169:3223–3231.PubMedGoogle Scholar
  83. 83.
    Tulzo YL, Pangault C, Gacouin A, et al: Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002;18:487–494.PubMedGoogle Scholar
  84. 84.
    Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM: The role of the complement system in ischemia-reperfusion injury. Shock 2004;21:401–409.PubMedGoogle Scholar
  85. 85.
    Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC: Limitation of reperfusion injury by a monoclonal antibody to c5a during myocardial infarction in pigs. Am J Physiol 1995;268:H448–00H457.PubMedGoogle Scholar
  86. 86.
    Arumugam TV, Shiels IA, Woodruff TM, Reid RC, Fairlie DP, Taylor SM: Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J Surg Res 2002;103:260–267.PubMedGoogle Scholar
  87. 87.
    Arumugam TV, Shiels IA, Strachan AJ, Abbenante G, Fairlie DP, Taylor SM: A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int 2003;63:134–142.PubMedGoogle Scholar
  88. 88.
    Arumugam TV, Woodruff TM, Stocks SZ, et al: Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J Hepatol 2004;40:934–941.PubMedGoogle Scholar
  89. 89.
    Heller T, Hennecke M, Baumann U, et al: Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. J Immunol 1999;163:985–994.PubMedGoogle Scholar
  90. 90.
    Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL: Myocardial ane infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998;97:2259–2267.PubMedGoogle Scholar
  91. 91.
    Wada K, Montalto MC, Stahl GL: Inhibition of complement C5 reduces local and remote organ injury after intertinal ischemia/reperfusion in the rat. Gastroenterology 2001;120:126–133.PubMedGoogle Scholar
  92. 92.
    de Vries B, Köhl J, Leclercq WKG, et al: Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 2003;170:3883–3889.PubMedGoogle Scholar
  93. 93.
    Braun MC, Lahey E, Kelsall BL: Selective suppression of IL-12 production by chemoattractants. J Immunol 2000;164:3009–3017.PubMedGoogle Scholar
  94. 94.
    Wittmann M, Zwirner J, Larsson VA, et al: C5a suppresses the production of IL-12 by IFN-gamma-primed and lipopolysaccharide-challenged human monocytes. J Immunol 1999;162:6763–6769.PubMedGoogle Scholar
  95. 95.
    Haggar A, Hussain M, Lönnies H, et al: Extracellular adherence protein fromStaphylococcus aureus enhances internalization into eukaryotic cells. Infect Immun 2003;71:2310–2317.PubMedGoogle Scholar
  96. 96.
    Karp CL, Grupe A, Schadt E, et al: Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 2000;1:221–226.PubMedGoogle Scholar
  97. 97.
    Karp CL, Wills-Karp M: Complement and IL-12: yin and yang. Microbes Infect 2001;3:109–119.PubMedGoogle Scholar
  98. 98.
    Abe M, Shibata K, Akatsu H, et al. Contribution of anaphylatoxin C5a a to late airway responses after repeated exposure of antigen to allergic rats. J Immunol 2001;167:4651–4660.PubMedGoogle Scholar
  99. 99.
    Köhl J, Baelder R, Lewkowich IP, et al: A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest 2006;116:783–796.PubMedGoogle Scholar
  100. 100.
    Shushakova N, Skokowa J, C5a anaphylatoxin is a major regulator of activating versus inhibitory fcgammars in immune complex-induced lung disease. J Clin Invest 2002;110:1823–1830.PubMedGoogle Scholar
  101. 101.
    Skokowa J, Ali SR, Felda O, et al: Macrophages induce the inflammatory response in the pulmonary arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation. J Immunol 2005;174:3041–3050.PubMedGoogle Scholar
  102. 102.
    Kumar V, Ali SR, Konrad S, et al: Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. J Clin Invest 2006;116:512–520.PubMedGoogle Scholar
  103. 103.
    Rooijakkers S, van Strijp JA: Bacterial complement evasion. Mol Immunol 2007;44:23–32.PubMedGoogle Scholar
  104. 104.
    Rooijakkers SHM, Ruyken M, Roos A, et al: Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Natl Immunol 2005;6:920–927.Google Scholar
  105. 105.
    Lee LYL, Liang X, Höök M, Brown EL: Identification and characterization of the C3 binding domain of theStaphylococcus aureus extracellular fibrinogen-binding protein (Efb). J Biol Chem 2004;279:50710–50716.PubMedGoogle Scholar
  106. 106.
    Lee LYL, Höök M, Haviland D, et al: Inhibition of complement activation by a secretedStaphylococcus aureus protein. J Infect Dis 2004;190:571–579.PubMedGoogle Scholar
  107. 107.
    Al-Shangiti AM, Naylor CE, Nair SP, Briggs DC, Henderson B, Chain BM: Structural relationships and cellular tropism of staphylococcal superantigen-like proteins. Infect Immun 2004;72:4261–4270.PubMedGoogle Scholar
  108. 108.
    Al-Shangiti AM, Nair SP, Chain BM: The interaction between staphylococcal superantigen-like proteins and human dendritic cells. Clin Exp Immunol 2005;140:461–469.PubMedGoogle Scholar
  109. 109.
    Langley R, Wines B, Willoughby N, Basu I, Proft T, Fraser JD: The staphylococcal superantigen like protein 7 binds IgA and complement C5 and inhibits IgA-Fc alpha RI binding and serum killing of bacteria. J Immunol 2005;174:2926–2933.PubMedGoogle Scholar
  110. 110.
    Wines BD, Willoughby N, Fraser JD, Hogarth PM: A competitive mechanism for staphylococcal toxin SSL7 inhibiting the leukocyte IgA receptor, Fc alpha RI, is revealed by SSL7 binding at the Calpha 2/Calpha 3 interface of IgA. J Biol Chem 2006;281:1389–13930.PubMedGoogle Scholar
  111. 111.
    Veldkamp KE, Van Kessel KP, Verhoef J, Van Strijp JA: Staphylococcal culture supernates stimulate human phagocytes. Inflammation 1997;21:541–551.PubMedGoogle Scholar
  112. 112.
    de Haas CJ, Veldkamp KE, Peschel A, et al: Chemotaxis inhibitory protein ofStaphylococcus aureus, a bacterial antiinflammatory agent. J Exp Med 2004;199:687–695.PubMedGoogle Scholar
  113. 113.
    Bronner S, Montei H, Prévost G: Regulation of virulence determinants inStaphylococcus aureus: complexity and applications. Fems Microbiol Rev 2004;28:183–200.PubMedGoogle Scholar
  114. 114.
    Novick RP: Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol Microbiol 2003;48:1429–1449.PubMedGoogle Scholar
  115. 115.
    Rooijakkers SHM, Ruyken M, van Roon J, van Kessel KPM, van Strijp JAG, van Wamel WJB: Early expression of SCIN and CHIPS drives instant immune evasion byStaphylococcus aureus. Cell Microbiol 2006;8:1282–1293.PubMedGoogle Scholar
  116. 116.
    Postma B, Poppelier MJ, van Galen JC, et al: Chemotaxis inhibitory protein of staphylococcus aureus binds specifically to the C5a and formylated peptide receptor. J Immunol 2004;172:6994–7001.PubMedGoogle Scholar
  117. 117.
    Falk W, Harvath L, Leonard EJ: Only the chemotactic subpopulation of human blood monocytes expresses receptors for the chemotactic peptiden-formylmethionyl-leucyl-phenylalanine. Infect Immun 1982;36:450–454.PubMedGoogle Scholar
  118. 118.
    Huey R, Hugli TE: Characterization of a C5a receptor on human polymorphonuclear leukocytes (PMN). J Immunol 1985;135:2063–2068.PubMedGoogle Scholar
  119. 119.
    Pike MC, Fischer DG, Koren HS, Snyderman R: Development of specific receptors for n-formylated chemotactic peptides in a human monocyte cell line stimulated with lymphokines. J Exp Med 1980;152:31–40.PubMedGoogle Scholar
  120. 120.
    Haas PJ, de Haas CJ, Kleibeuker W, et al: N-terminal residues of the chemotaxis inhibitory protein ofStaphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor. J Immunol 2004;173:5704–5711.PubMedGoogle Scholar
  121. 121.
    Haas P, de Haas CJC, Poppelier MJJC, et al: The structure of the C5a receptor-blocking domain of chemotaxis inhibitory protein of staphylococcus aureus is related to a group of immune evasive molecules. J Mol Biol 2005;353:859–872.PubMedCrossRefGoogle Scholar
  122. 122.
    Rahimpour R, Mitchell G, Khandaker MH, et al: Bacterial superantigens induce down-modulation of CC chemokine responsiveness in human monocytes via an alternative chemokine ligand-independent mechanism. J Immunol 1999;162:2299–2307.PubMedGoogle Scholar

Copyright information

© Humana Press Inc 2007

Authors and Affiliations

  • Pieter-Jan Haas
    • 1
  • Jos van Strijp
    • 1
  1. 1.Eijkman-Winkler Center for Experimental MicrobiologyUniversity Medical Center Utrecht, HP:G04-614UtrechtThe Netherlands

Personalised recommendations